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ante for those betting types who strive
to predict the phenotype of mice lacking
the E type cyclins or cdk2, or of normal
human cells treated to lack these mole-
cules. Based on current dogma, many
would place their money on an absolute
requirement for cdk2 or E cyclins in nor-
mal cell cycles. Given the work present-
ed by Tetsu and McCormick, the payoff
may go to those betting on less pro-
found phenotypes, and such experi-
ments will likely force the preparation of
a new set of model slides for all those
with interest in cdk2’s role in mam-
malian cell cycle control.
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In the United States and much of the
Western world, breast cancer rivals lung
cancer as the most frequent cause of
cancer-related death in women, with
upwards of 12 percent of women diag-
nosed with breast cancer during their life-
times. While breast cancer mortality
appears to have shown some encourag-
ing decreases in the recent past, present-
ly, about 25% of women diagnosed with
breast cancer will die of the disease
(Baselga and Norton, 2002). Hormonal
factors play a key role in normal breast
development and in growth and progres-
sion of breast cancer.
Perhaps chief among the hormonal
factors involved in breast cancer is the
ovarian steroid hormone estrogen. The
biological actions of estrogen are
dependent on the cellular function of a
high-affinity estrogen receptor (ER)
(McDonnell and Norris, 2002). Two estro-
gen receptors—ERα and ERβ—have
been identified, but most estrogenic
responses appear to require ERα. Upon
binding estrogen or other ligands, ER is
released from its inhibition by a large heat
shock protein complex. Following dimer-
ization, ER activates transcription of spe-
cific cellular genes via direct and indirect
interactions with their regulatory regions.
In breast cancer cells expressing ER,
estrogen has potent effects on cell prolif-
eration, differentiation, and survival, per-
haps in part via estrogen’s ability to affect
the cellular response to various growth
factors and other cues from surrounding
extracellular matrix and stromal cells.
While ER expression in breast cancer is
generally associated with a better clinical
outcome, the clinical utility of ER as a
prognostic marker is modest. Rather, the
principal value of defining the ER status
(and the progesterone receptor status) of
a breast cancer is for prediction of the
patient’s likely response to systemic ther-
apy, particularly adjuvant therapy with
tamoxifen, a selective estrogen receptor
modifier and antiestrogenic agent in the
breast (Baselga and Norton, 2002).
Besides hormonal and other envi-
ronmental factors, germline and somatic
mutations and gene expression changes
play key roles in breast cancer initiation
and progression. There is great interest
in defining how the various mutations
and gene expression changes contribute
to breast cancer development and its
aggressive behavior, especially because
recent studies have indicated that partic-
ular gene expression signatures in
breast cancer are associated with good
prognosis and other signatures are
associated with poor prognosis (van de
Vijver et al., 2002). A major challenge for
workers pursuing gene expression
Connecting estrogen receptor function, transcriptional repression,
and E-cadherin expression in breast cancer
A recent paper in Cell (Fujita et al., 2003) demonstrates that MTA3, a novel component of the Mi-2/NuRD transcriptional repres-
sion complex, is an estrogen receptor-regulated inhibitor of the Snail zinc finger transcription factor in breast cancer. Given
the important role of Snail in repressing E-cadherin transcription and the function of E-cadherin as a tumor suppressor pro-
tein and regulator of epithelial architecture, the findings offer potentially significant new insights into cancer pathogenesis.
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analyses in breast cancer is to define key
signaling pathways and transcriptional
regulators impacting on expression of
critical target genes, such as protoonco-
genes or tumor suppressor genes. A
recent paper in Cell (Fujita et al., 2003)
appears to offer new and exciting
insights into mechanisms by which
expression of the E-cadherin tumor sup-
pressor gene may be silenced in some
breast and other cancers.
E-cadherin is the prototypic member
of the classic cadherin family of single-
pass transmembrane glycoproteins
mediating Ca2+-dependent cell-cell adhe-
sion, and it plays essential roles in devel-
opment, cell polarity, and tissue
morphology (Takeichi, 1995). E-cad-
herin’s extracellular domain interacts in a
homotypic fashion with E-cadherin mole-
cules on an opposing cell, and its cyto-
plasmic domain is linked directly and/or
indirectly to the actin cytoskeleton at the
adherens junction via interactions with
catenins (Figure 1). Disruption of the cad-
herin-catenin complex has been seen in
cancers arising in many tissues and has
been correlated with pathological and
clinical features, such as tumor dediffer-
entiation, infiltrative growth, lymph node
metastasis, and a worse patient progno-
sis. Maybe the strongest evidence in sup-
port of a causal role for cadherin
alterations in cancer pathogenesis is the
observation that germline mutations in
the gene encoding E-cadherin (known as
CDH1) strongly predispose affected indi-
viduals to diffuse-type gastric cancer and
more modestly to breast carcinoma
(Pharoah et al., 2001). CDH1 inactivation
seems to adhere to the Knudson two-hit
model for tumor suppressor gene inacti-
vation, with biallelic CDH1 defects in can-
cers arising in those carrying germline
CDH1 mutations. Further evidence of a
causal role for E-cadherin defects in can-
cer has been offered by the identification
of somatic inactivating CDH1 gene muta-
tions in upwards of 50% of diffuse-type
gastric and infiltrative lobular breast car-
cinomas and in subsets of other malig-
nancies (Hajra and Fearon, 2002).
While immunohistochemical studies
have demonstrated that reduced or
absent E-cadherin expression is common
in many types of carcinomas, in the
majority of cancers where expression is
lost, CDH1 mutations are rare or absent
(Hajra and Fearon, 2002). Proposed epi-
genetic mechanisms for E-cadherin inac-
tivation include alterations in expression
and/or function of trans-acting factors that
regulate CDH1 gene transcription, hyper-
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Figure 1. Model of factors and presumed mechanisms contributing to estrogen receptor-mediated activation of MTA3; MTA3′s repression of Snail;
and Snail’s repression of E-cadherin
The model is based largely on the data presented in the article by Fujita et al. (2003). E-cadherin functions as a cell-cell adhesion molecule at
adheren junctions of epithelial cells via homotypic interactions with E-cadherin molecules on neighboring cells and cytoplasmic interactions with
the catenins, α-actinin (or vinculin), and the actin cortical cytoskeleton. Expression of the MTA3 (metastatic tumor antigen 3) gene is regulated
indirectly by ER function. MTA3 is a component of the Mi-2/NuRD transcriptional repression complex, and other components include the nucleo-
some-stimulated ATPase Mi-2, the methyl CpG binding protein-related protein MBD3, histone deacetylase 1 (HDAC1), and potentially other
unknown proteins (e.g., X). The MTA3-containing complex represses transcription of the gene encoding the Snail zinc finger DNA binding protein
via binding to Snail promoter elements. The Snail protein binds to multiple E box elements in the E-cadherin promoter and likely mediates repres-
sion through interactions with other proteins, such as HDACs. The Snail-related protein Slug also functions to repress E-cadherin transcription, but
Slug is not regulated by the MTA3 complex. A metastatic tumor antigen 1 isoform (termed MTA1s) can sequester ER in the cytoplasm, but the rela-
tionship of MTA1s action to expression of MTA3, Snail, and E-cadherin remains unknown.
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methylation of the CDH1 promoter, and
chromatin-mediated effects. Consistent
with a role for trans-acting factors, analy-
sis of breast cancer somatic cell hybrids
suggests that a dominant repression
pathway extinguishes CDH1 transcription
via effects on its proximal promoter (Hajra
and Fearon, 2002), and three E box ele-
ments in this region have been proposed
to be critical in silencing of CDH1 tran-
scription in cancer (Hajra et al., 2002). A
number of transcription factors may bind
to the CDH1 E box elements to repress
transcription, including the zinc finger
transcription factor Snail (Cano et al.,
2000; Batlle et al., 2000), the Snail-related
factor Slug (Hajra et al., 2002), and SIP1
(ZEB-2) (Comijn et al., 2001). Increased
expression of Snail and/or Slug has been
correlated with loss of E-cadherin expres-
sion in cancers of various types (Batlle et
al., 2000; Poser et al., 2001; Hajra et al.,
2002; Blanco et al., 2002).
While the prior results offered evi-
dence of an association between expres-
sion of Snail and/or other transcriptional
repressors and loss of E-cadherin
expression in cancer, knowledge was
lacking on the specific mechanisms con-
tributing to aberrant expression of Snail
and other transcriptional repressors in
cancer. In their article, Fujita and cowork-
ers provide compelling evidence that
MTA3, a novel component of the Mi-
2/NuRD (for nucleosome remodeling
and deacylation) transcription repression
complex, can directly repress Snail tran-
scription. Various genetic and biochemi-
cal studies had previously implicated the
Mi-2/NuRD complex in transcriptional
repression via its intrinsic histone
deacetylase (HDAC) and nucleosome-
stimulated ATPase activities and its abili-
ty to interact with DNA binding proteins
(Becker and Horz, 2002). Although some
prior studies had implicated overexpres-
sion of the roughly 80 kDa metastatic
tumor antigen 1 (MTA1) protein in inva-
sive and metastatic growth (Toh et al.,
1997), Fujita and colleagues focused
attention on the related factor MTA3.
After demonstrating MTA3 was a bona
fide component of the Mi-2/NuRD com-
plex and not present in complexes with
MTA1 or MTA2, the authors established
that the approximately 60 kDa MTA3 pro-
tein could function in model assays to
repress gene expression through HDAC-
dependent mechanisms. Of some inter-
est, in breast cancer cells, expression of
endogenous MTA3 transcripts and pro-
tein was dependent on activation of ER,
though the MTA3 gene did not appear to
be directly activated by ER.
In large part because of the connec-
tion between ER function and MTA3
expression, Fujita and colleagues specu-
lated that changes in epithelial architec-
ture seen in ER-negative breast cancer
might result from a loss of MTA3 func-
tion. Moreover, because of E-cadherin’s
role in epithelial architecture, the authors
wondered whether MTA3 might play a
role in regulation of E-cadherin, perhaps
via MTA3′s ability to repress expression
of factors that might themselves repress
CDH1 gene transcription, such as Snail
or Slug. Remarkably, MTA3, but not the
related protein MTA1, had potent
inhibitory effects via HDAC-dependent
mechanisms on expression of Snail but
not Slug (Figure 1). Using chromatin
immunoprecipitation approaches, the
MTA3 complex was found to associate
with Snail promoter elements. MBD3, a
protein closely related to the methyl CpG
binding protein MBD2, was also present
in the MTA3 complex. In the cell lines
studied, the authors used both overex-
pression and RNA interference
approaches to buttress their claims
about the role of MTA3 in repression of
Snail and the role of Snail in repression
of E-cadherin. To establish the relevance
of their claims for primary breast can-
cers, the authors pursued studies of pri-
mary breast carcinoma specimens,
demonstrating MTA3 expression was
well correlated with that of ER and E-
cadherin. Finally, analysis of published
microarray gene expression data from a
large panel of primary breast carcino-
mas for which ER status was known
yielded mixed but generally supportive
data for the authors’ claims about the
relationships of MTA3 expression to ER,
Snail, and E-cadherin expression.
Overall, the data in the Fujita et al.
article are compelling, and the findings
enhance understanding of mechanisms
contributing to loss of E-cadherin func-
tion in cancer. The results also implicate
intact ER function as a potentially crucial
factor in differentiation and maintenance
of normal epithelial architecture in breast
epithelium. In spite of the advances
offered by the work, gaps in our knowl-
edge remain. Because ER did not
appear to activate MTA3 expression
directly and ER and MTA3 expression
were not tightly correlated in primary
breast cancer specimens, it seems that
critical intermediary factors responsible
for ER’s apparent role in regulating MTA3
gene expression remain to be defined. A
curious, but potentially interesting, side
note with respect to the ER-MTA3 con-
nection is the observation by Kumar et
al. (2002) that an alternatively spliced
form of MTA1 present in some breast
cancer cells, termed MTA1s, sequesters
ERα in the cytoplasm and inhibits its
function. Besides the uncertainties in the
ER-MTA3 connection, the specific DNA
binding factors and cofactors responsi-
ble for targeting MTA3 and other
Mi/NuRD repression complex compo-
nents to the Snail promoter are
unknown. Nor is it yet clear what deter-
mines the specificity of the action of
MTA3, but not MTA1 or MTA2, on Snail
gene expression. Because Snail and E-
cadherin show at best a rather modest
inverse correlation in their expression in
breast cancers (Blanco et al., 2002;
Hajra et al., 2002), uncertainties remain
regarding the relative contribution of
Snail versus other potential repressors
of E-cadherin, such as Slug or SIP1, in
E-cadherin silencing in breast cancer.
Also, the ability of Snail and other repres-
sors to extinguish E-cadherin transcrip-
tion in cancer cells presumably depends
on other factors, including likely HDACs
and possibly other histone-modifying
factors, as well as perhaps DNA methyl-
transferases to insure that E-cadherin
transcription is fully “locked off.”
Moreover, while E-cadherin is often sug-
gested to be an “invasion suppressor,”
definitive data on the biochemical and
phenotypic consequences of its reduced
or absent expression in cancer cells are
largely lacking. Nonetheless, in spite of
the uncertainties and unanswered ques-
tions, the findings of Fujita et al. highlight
important avenues for further investiga-
tion. Indeed, their encouraging results
suggest that we can expect much
progress in the relatively near future in
advancing understanding of the various
transcription factors and chromatin
remodeling proteins that play crucial
roles in regulating expression of key
genes in the cancer process.
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